



Press release

Regulated information

IBA – DATA CONCERNING TRANSPARENCY

Louvain-la-Neuve, Belgium, 27 June 2014 - IBA (Ion Beam Applications SA), the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, communicates today the basic and additional data as per Article 15 §1 al.1 of the Transparency Law, following its capital increase and convertible bonds issue in favour of SRIW and SFPI and its issue of warrants dated 27 June 2014.

Data concerning transparency Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008

Communication of the basic data as per Article 15 §1 al.1 of the Law

• Total capital:	EUR 39 575 227.94
• Total number of securities conferring the voting right: 12 702 489 with VVPR strips)	28 196 787 (of which
• Total number of voting rights (= the denominator):	28 196 787
• Total number of securities conferring the voting right, by category:	N/A
• Total number of voting rights, by category:	N/A

Communication of the additional data as per Article 15 §1 al.2 of the Law

• Total number of convertible bonds conferring the voting right:	0
• Total number of rights, materialized or not by certificates, giving the right to subscribe to newly issued securities conferring the voting right (e.g. warrants):	2 855 846
• Total number of voting rights which would result from the exercise of these conversion or subscription rights:	2 855 846
• Total number of shares without voting right:	0

Statutory thresholds as per Article 18 of the Law

The applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percent.

- Ends -

About IBA

IBA (Ion Beam Applications S.A.), is a cancer diagnostics and treatment company and the worldwide technology leader in the field of proton therapy. The Company's expertise lies in the development of next generation proton therapy technologies and radiopharmaceuticals that provide oncology care providers with premium quality services and equipment, including IBA's leading fully integrated IntegraLab[®] radiopharmacy system, and Dosimetry advanced solutions for Quality Assurance of medical equipment and increased patient safety.



Press release |

Regulated information

Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors, providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Contact person

IBA

Caroline Hardy
Corporate Legal Counsel
+32 10 201 159
caroline.hardy@iba-group.com